Aurion Biotech has won the Prix Galien Award for Best Startup in Biotech/Pharma, recognizing the company’s clinically validated cell therapy for corneal endothelial dystrophies, according to a press release.
“We are so grateful to the Prix Galien Awards Committee for conferring this incredible award on Aurion Biotech,” Greg Kunst, MBA, president and CEO of Aurion Biotech, told Healio/OSN. “We believe it’s a tribute to our patients, employees, scientists and physicians who are collaborating to bring this transformational cell therapy to millions of people suffering